

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

1 Title

2 **Childhood Immuno-metabolic Markers and Risk of Depression and Psychosis in**
3 **Adulthood: A Prospective Birth Cohort Study**

4 Article Type

5 Original Research Paper

6 Authors

7 Donnelly NA^{1,2}; Perry BI^{3,4}; Jones HJ^{1,5,6}; Khandaker, GM^{1,2,3,4,5,6}

8 Affiliations

9 ¹ Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School,
10 University of Bristol, Bristol, UK

11 ² Avon and Wiltshire Mental Health Partnership NHS Trust

12 ³ Department of Psychiatry, University of Cambridge

13 ⁴ Cambridgeshire and Peterborough NHS Foundation Trust

14 ⁵ NIHR Bristol Biomedical Research Centre, University of Bristol, Bristol, UK

15 ⁶ MRC Integrative Epidemiology Unit, University of Bristol

16 Keywords

17 ALSPAC; Depression; Psychosis; Leptin; Adipokines; Negative Symptoms

18 Word Count

19 Total: 4091 words

20 Introduction: 613 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

21 Discussion: 1318 words

22 List of Figures and Tables

23 The manuscript includes the following figures:

24 Figure 1: Correlations between Childhood Immuno-metabolic Markers

25 Figure 2: Associations of Childhood Metabolic Hormones with Adult Depression and
26 Psychosis Measures

27 Figure 3: Associations of Childhood Immuno-Metabolic Factor Scores with Adult
28 Depression and Psychosis Measures

29 The manuscript includes the following tables:

30 Table 1: Associations of Childhood Metabolic Hormones with Adult Depression and
31 Psychosis Measures in the Whole Sample

32 Table 2: Associations of Childhood Immuno-Metabolic Factors with Adult Depression
33 and Psychosis Measures in the Whole Sample

34 Abstract

35 Background

36 Metabolic and inflammatory disorders commonly co-occur with depression and psychosis,
37 with emerging evidence implicating immuno-metabolic dysfunction in their aetiology.

38 Previous studies have reported metabolic dysfunction and inflammation in adults with
39 depression and psychosis. However, longitudinal studies testing the direction of association,
40 and the effects of different dimensions of early-life immuno-metabolic dysfunction on adult
41 psychopathology, are limited.

42 Methods

43 Using data from 3875 birth cohort participants we examined longitudinal associations of
44 three metabolic hormones (leptin, adiponectin, insulin) at age 9 with risks for depression-
45 and psychosis-spectrum outcomes at age 24. In addition, using nine immuno-metabolic
46 biomarkers, we constructed an exploratory bifactor model showing a general immuno-
47 metabolic factor and three specific factors (adiposity, inflammation, and insulin resistance),
48 which were also used as exposures.

49 Results

50 Childhood leptin was associated with adult depressive episode (adjusted odds ratio
51 (aOR)=1.28; 95% CI, 1.00-1.64) and negative symptoms (aOR=1.12; 95% CI, 1.05-1.20).

52 The general immuno-metabolic factor was associated with depressive symptoms
53 (aOR=1.05; 95% CI, 1.01-1.08) and psychotic experiences (aOR=1.20; 95% CI, 1.01-1.42).

54 The adiposity factor was associated with negative symptoms (aOR=1.07; 95% CI 1.02-1.12).

55 All associations tended to be stronger in women, though 95% credible intervals overlapped
56 with that for men. In women, the inflammatory factor was associated with depressive
57 episode (aOR=1.23; 95% CI, 1.01-1.47) and atypical depressive symptoms (aOR=1.10; 95%
58 CI, 1.02-1.19).

59 **Conclusions**

60 While general immuno-metabolic dysfunction in childhood may contribute to risks for both
61 psychotic and depressive symptoms in adulthood, childhood adiposity and inflammation are
62 linked to affective (depressive, atypical, and negative) symptoms.

63 1. Introduction

64 Immuno-metabolic alterations are present in depressive and psychotic disorders, and are
65 associated with excess mortality (Hoang et al., 2013; Milaneschi et al., 2020, 2019;
66 Vancampfort et al., 2015). The prevalence of cardiometabolic disease (Penninx et al., 2001;
67 van Melle et al., 2004), autoimmune inflammatory conditions (Benros et al., 2011; Eaton et
68 al., 2006), and levels of circulating inflammatory markers (Khandaker et al., 2014; Osimo et
69 al., 2019), are higher in people with depression and psychosis compared with controls.
70 However, the direction of these relationships remains unclear. For example, while
71 psychotropic medications can increase predisposition to cardiometabolic disorders
72 (Vancampfort et al., 2015), there is evidence that predisposition towards cardiometabolic
73 dysfunction predates treatment with psychotropic medications (Benseñor et al., 2012; Perry
74 et al., 2016, 2021b; Pillinger et al., 2017). Therefore, longitudinal studies are required to
75 address the issue of direction of association.

76 Emerging evidence from longitudinal studies suggests that inflammation may predate the
77 onset of depression and psychosis. Using longitudinal data from the Avon Longitudinal Study
78 of Parents and Children (ALSPAC) and Northern Finland Birth Cohort (NFBC) 1986 birth
79 cohorts (Khandaker et al., 2014; Metcalf et al., 2017; Perry et al., 2021b), we have reported
80 associations between higher circulating levels of interleukin 6 (IL-6) and C-reactive protein
81 (CRP) in childhood and adolescence with risk of depression and psychosis subsequently in
82 adulthood. Similar longitudinal associations have also been reported from the UK Whitehall
83 (Gimeno et al., 2009), Dutch Generation R (Zalli et al., 2016) and the Netherlands Study of
84 Depression and Anxiety (NESDA) (Lamers et al., 2020) cohorts. Using longitudinal repeated
85 measures data from the ALSPAC cohort, we have reported higher risk of psychosis in
86 adulthood associated with persistently high insulin levels across childhood, adolescence and
87 early-adulthood, which may vary by sex (Perry et al., 2021b). These findings point to a role
88 of immuno-metabolic alterations in childhood, a critical period for the development of the
89 nervous, immune, and endocrine systems, in the aetiology of psychiatric disorders.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

90 Despite previous studies reporting obesity, altered glucose-insulin homeostasis, lipids, and
91 other metabolic dysfunction in people with depression, psychosis and young people with
92 psychotic experiences (Milaneschi et al., 2019; Perry et al., 2019; Vancampfort et al., 2015),
93 longitudinal studies of childhood metabolic markers and subsequent depression and
94 psychosis are relatively scarce. Particularly lacking are studies of metabolic hormones such
95 as insulin, adiponectin and leptin, which are key neuroendocrine regulators of energy
96 homeostasis. Immuno-metabolic biomarkers are interlinked and have pleiotropic functions.
97 For instance, obesity is associated with systemic low-grade inflammation (Timpson et al.,
98 2011; Yudkin et al., 1999), while insulin and leptin are influenced by inflammation and
99 obesity (Considine et al., 1996; Jerry and Lesley, 2006; van Dielen et al., 2001). Commonly
100 known as a satiety hormone, leptin is structurally similar to IL-6 and may have inflammatory
101 functions (Abella et al., 2017). Additionally, previous studies have typically considered only a
102 few immune or metabolic markers in isolation and ignored the underlying structure of
103 covariance between biomarkers.

104 To address the issue of direction of association, we have carried out a longitudinal study
105 testing the associations of three key metabolic hormones (insulin, leptin and adiponectin),
106 measured in childhood at age 9 years, with several outcomes across the spectrum of
107 depression (depressive episode, total symptom score, and atypical symptom score) and
108 psychosis (psychotic disorder, at-risk mental state, psychotic experiences, negative
109 symptoms) at age 24 years, in a whole analysis sample and in men and women separately,
110 using data from the ALSPAC birth cohort. Furthermore, combining these hormones with
111 related immuno-metabolic markers (BMI, LDL, HDL, triglycerides, IL-6, and CRP), also
112 measured at age 9, we identified factors representing general and specific dimensions of
113 early-life immuno-metabolic dysfunction, and tested their associations with psychiatric
114 outcomes at age 24.

115 2. Materials and Methods

116 2.1 Cohort Profile

117 We used data from the ALSPAC birth cohort (Boyd et al., 2013; Fraser et al., 2013;
118 Northstone et al., 2019), which recruited 14,541 pregnant women in the Avon area of the
119 United Kingdom between 1990 and 1992; of these initial pregnancies 13,988 children were
120 alive at 1 year of age. Further phases of recruitment occurred when the oldest children in the
121 cohort were approximately 7 years of age, resulting in an additional 913 children being
122 enrolled; giving a total cohort size of 15,454 pregnancies, resulting in 15,589 deliveries, of
123 which 14,901 were alive at 1 year of age. The study is considered to be representative of the
124 UK population (Golding et al., 2001).

125 Study data are collected and managed using the REDCap (Research Electronic Data
126 Capture) tools hosted at the University of Bristol (Harris et al., 2019, 2009). Children and
127 parents have been subsequently followed up with clinic and questionnaire assessments for a
128 range of health outcomes. The ALSPAC study website contains details of all available data
129 through a fully searchable data dictionary [http://www.bristol.ac.uk/alspac/researchers/our-](http://www.bristol.ac.uk/alspac/researchers/our-data/)
130 [data/](http://www.bristol.ac.uk/alspac/researchers/our-data/).

131 Ethical approval for the study was obtained from the ALSPAC Ethics and Law Committee
132 and the Local Research Ethics Committees
133 (<http://www.bristol.ac.uk/alspac/researchers/research-ethics/>). Consent for biological
134 samples was collected in accordance with the UK Human Tissue Act (2004). Informed
135 consent for the use of data collected via questionnaires and clinics was obtained from
136 participants following the recommendations of the ALSPAC Ethics and Law Committee at
137 the time.

138 This study is reported in line with the Strengthening the Reporting of Observational Studies
139 in Epidemiology (STROBE) reporting guideline for cohort studies.

140

141 2.2 Measurement of childhood immuno-metabolic biomarkers at age 9

142

143 2.2.1 Metabolic Hormones

144 Leptin, adiponectin and random insulin were measured at the cohort age 9 clinic visit

145 (**Supplementary Table 1**). As previously described (Falaschetti et al., 2010), non-fasting

146 blood samples were collected during clinic visits, using standard aseptic procedure and

147 immediately spun and frozen for long-term storage at -80°C. Blood biomarkers were

148 assayed in 2008 after a median of 7.5 years in storage with no previous freeze–thaw cycles

149 during storage. We did not include fasting insulin in this study due to the lower sample size

150 available for that measure (Ong et al., 2004). Leptin (ng/ml) was measured by an in-house

151 enzyme-linked immunosorbent assay (ELISA) validated against commercial methods.

152 Adiponectin (ng/ml) and random insulin (mU/l) was measured using an ultrasensitive

153 automated microparticle enzyme immunoassay (Mercodia), which does not cross-react with

154 proinsulin. All assay coefficients of variation were <6%.

155 2.2.2 Other Metabolic Biomarkers

156 We included plasma lipids (LDL, HDL and triglycerides (mmol/l)), also measured at the

157 cohort age 9 clinic visit (**Supplementary Table 1**). All were measured by a modification of

158 the standard Lipid Research Clinics Protocol using enzymatic reagents for lipid

159 determination.

160 2.2.3 Inflammatory Biomarkers

161 We included IL-6 and CRP, which were also measured at the cohort age 9 clinic visit

162 (**Supplementary Table 1**). IL-6 (pg/ml) was measured by ELISA (R&D systems, Abingdon,

163 UK), and CRP (mg/l) was measured by automated particle-enhanced immunoturbidimetric

164 assay (Roche UK, Welwyn Garden City, UK).

165 2.3 Assessment of Psychiatric Outcomes at age 24

166 2.3.1 Psychosis-Spectrum Outcomes

167 Psychotic positive symptoms were measured at age 24 with the psychosis-like symptoms
168 (PLIKS) interview (Sullivan et al., 2020; Zammit et al., 2013). Interviews were undertaken
169 using a semi-structured format by trained psychologists. Psychotic experiences (PEs) were
170 defined as symptoms in 3 domains (hallucinations, delusions, and thought interference)
171 occurring in the 6 months prior to the interview. After cross-questioning, PEs were rated as
172 absent, suspected, or definite. We included definite PEs as our outcome of interest.

173 Psychotic disorder was defined as definite PLIKS, not attributable to sleep or fever, which
174 occurred at least once a month in the past 6 months, which either caused the respondent to
175 seek professional help, was very upsetting/distressing, and/or had a negative impact on their
176 social/occupational life.

177 Cases of At Risk Mental State (ARMS) were defined by mapping the Comprehensive
178 Assessment of the At Risk Mental State (CAARMS) criteria onto the PLIKS variables (Perry
179 et al., 2021b). ARMs were defined as participants meeting CAARMS criteria for attenuated
180 psychosis (symptoms not reaching the psychosis threshold owing to levels of intensity or
181 frequency), brief limited intermittent psychosis (frank psychotic symptoms that resolved
182 spontaneously within 1 week), or the CAARMS psychosis group.

183 Negative symptoms at age 24 were measured using ten questions from a self-administered,
184 computerised version of the Community Assessment of Psychic Experiences (CAPE)
185 questionnaire (Jones et al., 2016; Konings et al., 2006; Stefanis et al., 2002). We generated
186 a single outcome variable by dichotomising responses to each question (each item was
187 rated by participants on a 1-4 scale, we grouped responses 1 and 2 as “symptom present”,
188 scoring 1 and responses 3 and 4 as “symptom absent”, scoring 0) and summing the
189 resultant scores, giving each participant a negative symptom score from 0 - 10.

190 2.3.2 Depression Outcomes

191 Depressive symptoms at age 24 were measured using a self-administered, computerised
192 version of the Clinical Interview Schedule, Revised (CIS-R) (Lewis et al., 1992). We took
193 three outcomes from the CIS-R data: (1) a dichotomous depressive episode variable, based
194 on a mapping of the CIS-R responses onto ICD-10 depression diagnostic criteria; (2) a
195 symptom score which was constructed as a sum of scores of the mood, thoughts, fatigue,
196 concentration, and sleep components for the CIS-R. This score ranged between 0 and 20.
197 We also derived (3): an atypical depression symptoms score composed of the sum of
198 participants scores on 4 items from the CIS-R: increased appetite, increased weight,
199 hypersomnia and low energy. Note that the CIS-R does not contain a measure of “lead
200 paralysis” as has been included in other measures of atypical depression (Lamers et al.,
201 2020), as this measure is not part of many common depression screening instruments
202 (Fried, 2017).

203 2.3.3 Confounders

204 We included maternal social class (determined using occupational status) and maternal
205 highest educational level as potential confounders. IL-6 and BMI at age 9 (weight in kg
206 divided by height in meters squared) were also included for analyses where they were not
207 part of the predictors.

208 2.4 Statistical Analysis

209 2.4.1 Data Transformation

210 We log₁₀-transformed all metabolic measures to give approximately normally distributed
211 data, except for adiponectin, which was already approximately normally distributed. All
212 continuous exposure and covariate variables were centred and standardised (mean value
213 subtracted and then divided by the standard deviation). Therefore, odds ratios (ORs)
214 represent change in outcome per SD change in exposure.

215 2.4.2 Exploratory Factor Analysis

216 Using adiponectin, insulin, leptin, IL-6, CRP, HDL, LDL, triglycerides, and BMI, we explored
217 the underlying factor structure of the immuno-metabolic phenotype at age 9. Before analysis,
218 we inverted HDL to match the cardiometabolic risk-increasing direction of other markers.

219 Factor analysis was done using the exploratory factor analysis (EFA) function in the
220 *EFAtools* R package. The number of factors was selected after inspecting the results of a
221 principal components analysis (**Supplementary Methods, Supplementary Figure 2**). We fit
222 a one factor, three factor, and a bifactor model with 3 subfactors, and compared model fit
223 (**Supplementary Table 2**). Compared to a one- or 3-factor model, the bifactor model was a
224 better fit to our data. We then extracted factor scores for each factor for each subject (**see**
225 **Supplementary Figure 2 and Supplementary Table 3 for factor loadings**).

226 2.4.3 Modelling Approach

227 We analysed data using R version 4.1.0 (R Development Core Team, 2017), fitting Bayesian
228 regression models using the *brms* (Bürkner, 2017) and *rstanarm* packages (Carpenter et al.,
229 2017). As the number of participants providing data for different outcomes varied, we fit each
230 model to the largest possible dataset of complete cases for all covariates, exposures and
231 outcomes (**see Supplementary Tables 4-6 for full details**).

232 We fit unadjusted models with a psychiatric outcome predicted by our exposure variables of
233 interest (leptin, adiponectin and insulin). Next, we fit adjusted models with BMI at age 9, \log_{10}
234 IL-6, sex at birth and maternal socioeconomic class included as covariates. We also fit
235 adjusted sex-stratified models to all female and male participants separately. For models
236 using factor scores as exposures, we included all factor scores as exposures plus sex at
237 birth and maternal socio-economic class as covariates.

238 We used regularising priors for all models (McElreath, 2018), calculating model estimate and
239 the 95% credible interval, using the median and the highest density interval method. We
240 present as summary statistics the probability of direction, which can be considered

241 analogous to the frequentist p-value (Makowski et al., 2019a, 2019b), and the Region of
242 Practical Equivalence (ROPE), the proportion of the posterior falling within a set region
243 around the null, here defined as an odds ratio in the range 0.9 – 1.1 (Kruschke and Liddell,
244 2018). **See supplementary methods for further details.**

245 2.4.4 Missing data

246 We analysed missingness in the dataset with two models: a model for missingness of clinic
247 data at age 9, with predictors of maternal education, maternal social class and ethnicity and
248 sex of the child; and a model for missingness for age 24 psychiatric data in the set of
249 participants who had blood tests at age 9, with predictors of maternal education, maternal
250 social class, ethnicity and sex of the child, and age 9 adiponectin, random insulin and leptin,
251 IL-6 and BMI.

252 2.4.5 Data Availability

253 In line with the ALSPAC data access policy, all raw data used for the work presented can be
254 accessed by other investigators by making a request to the ALSPAC study executive (see
255 <http://www.bristol.ac.uk/alspac/researchers/access/>).


256 3. Results

257 3.1 Childhood immuno-metabolic biomarker distributions, correlates, and 258 factor score calculation

259 Data on three metabolic hormones (insulin, leptin, adiponectin) and six related immuno-
260 metabolic biomarkers (BMI, HDL, LDL, triglycerides, IL-6, and CRP) were available from
261 total 3,875 participants at age 9 (**Supplementary Table 1**).

262 Higher leptin was associated with higher BMI (beta = 0.71; 95% credible interval [CI] 0.69-
263 0.73), female sex (beta for girls compared to boys = 0.48; 95% CI 0.44 - 0.51) and higher IL-
264 6 (beta = 0.04; 95% CI 0.02-0.05). Higher adiponectin was associated with lower BMI (beta
265 = -0.14; 95% CI -0.16 - -0.11), female sex (beta = 0.12; 95% CI 0.07-0.18) and higher IL-6
266 (beta = 0.04; 95% CI 0.01-0.06). Higher insulin was associated with higher BMI (beta = 0.22;
267 95% CI 0.19-0.25, **see Supplementary Figure 1 and Supplementary Table 7**).

268 Immuno-metabolic biomarkers were correlated (correlations ranged from -0.18 for
269 adiponectin-HDL to 0.75 for leptin-BMI, **Figure 1**). Using data for nine biomarkers we
270 calculated a bifactor model identifying a general immuno-metabolic factor (G, loading on all
271 biomarkers), and three sub-factors representing: (1) adiposity (loading on higher BMI, leptin
272 and LDL); (2) inflammation (loading on higher IL-6 and CRP); and (3) insulin resistance
273 (loading on higher triglycerides, insulin and lower HDL, **Supplementary Table 3**). There was
274 no relationship between sex or maternal class and G; all sub-factors had higher mean values
275 in females (**Supplementary Table 8**).



276

277 *Figure 1: Correlation between immuno-metabolic biomarkers at age 9 in the ALSPAC birth*
 278 *cohort.*

279 Matrix of correlations between all 9 immuno-metabolic markers measured at age 9. Colour
 280 represents correlation; negative correlations are represented in blue, positive correlations in
 281 red. Numerical values are correlation coefficients.


282 3.2 Associations of childhood metabolic hormones with depression and 283 psychosis risk in adulthood

284 3.2.1 Whole Sample Analysis

285 After adjusting for potential confounders, leptin at age 9 was associated with depressive
 286 episode (adjusted odds ratio [aOR] =1.28; 95% CI, 1.00-1.64) and negative symptoms at
 287 age 24 (aOR=1.12; 95% CI 1.05-1.20). Adiponectin was also associated with negative
 288 symptoms (aOR=1.05; 95% CI 1.00-1.09 **Figure 2, Table 1**). Insulin was not associated with
 289 any psychiatric outcome in our total sample.

290

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis



291

292 *Figure 2: Associations of Childhood Metabolic Hormones with Adult Depression and*
 293 *Psychosis Measures in the Whole Sample*

294 Plots of estimated odds ratios for the effect of our exposures (adiponectin, insulin and leptin)
 295 on psychiatric outcomes at age 24. Data are presented unadjusted and adjusted (for sex in
 296 the all-participant model, IL-6 at age 9, BMI at age 9 and maternal social class) and grouped
 297 by model: all participants, only females or only males. Thin bars represent the 95% credible
 298 interval, thicker bars the 66% credible interval, and dots the median of the posterior
 299 distribution for that parameter.

300 *Table 1: Associations of Childhood Metabolic Hormones with Adult Depression and Psychosis Measures in the Whole Sample*

| Outcome | Exposure | Unadjusted Analysis | | | Adjusted Analysis | | |
|------------------------------------|-------------|-----------------------|---------|----------|-----------------------|-------|----------|
| | | Estimated OR (95% CI) | pd | ROPE (%) | Estimated OR (95% CI) | pd | ROPE (%) |
| Depressive Episode | Leptin | 1.24 (1.06, 1.46) | 0.009 | 7.73 | 1.28 (1.00, 1.64) | 0.055 | 12.64 |
| | Adiponectin | 1.03 (0.88, 1.20) | 0.692 | 74.39 | 1.00 (0.85, 1.17) | 0.996 | 76.58 |
| | Insulin | 1.02 (0.88, 1.20) | 0.796 | 76.26 | 1.05 (0.88, 1.23) | 0.607 | 69.80 |
| Depressive Symptoms Score | Leptin | 1.08 (1.04, 1.11) | < 0.001 | 93.48 | 1.03 (0.97, 1.08) | 0.374 | 99.64 |
| | Adiponectin | 0.99 (0.96, 1.02) | 0.519 | 100.00 | 0.99 (0.95, 1.02) | 0.437 | 100.00 |
| | Insulin | 1.01 (0.98, 1.04) | 0.549 | 100.00 | 1.01 (0.98, 1.05) | 0.456 | 100.00 |
| Atypical Depressive Symptoms Score | Leptin | 1.11 (1.04, 1.18) | 0.002 | 45.73 | 1.00 (0.90, 1.10) | 0.987 | 95.25 |
| | Adiponectin | 1.00 (0.94, 1.07) | 0.937 | 99.88 | 1.00 (0.94, 1.06) | 0.985 | 99.86 |
| | Insulin | 0.98 (0.93, 1.05) | 0.611 | 99.70 | 0.98 (0.93, 1.04) | 0.572 | 99.71 |
| Negative Symptoms Score | Leptin | 1.04 (0.99, 1.08) | 0.103 | 99.83 | 1.12 (1.05, 1.20) | 0.001 | 33.27 |
| | Adiponectin | 1.05 (1.01, 1.10) | 0.015 | 98.78 | 1.05 (1.00, 1.09) | 0.038 | 99.25 |
| | Insulin | 1.02 (0.98, 1.06) | 0.400 | 100.00 | 1.02 (0.98, 1.07) | 0.296 | 99.94 |
| Psychotic Experiences | Leptin | 1.14 (0.96, 1.36) | 0.161 | 35.93 | 0.96 (0.73, 1.27) | 0.760 | 50.54 |
| | Adiponectin | 0.97 (0.80, 1.16) | 0.779 | 70.13 | 1.01 (0.84, 1.21) | 0.924 | 71.41 |
| | Insulin | 1.16 (0.97, 1.39) | 0.100 | 30.24 | 1.13 (0.95, 1.37) | 0.182 | 39.36 |
| Psychotic Disorder | Leptin | 1.11 (0.73, 1.60) | 0.604 | 34.23 | 1.23 (0.75, 2.06) | 0.433 | 22.66 |

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

| | | | | | | | |
|----------------|-------------|-------------------|-------|-------|-------------------|-------|-------|
| | Adiponectin | 1.05 (0.71, 1.53) | 0.817 | 38.34 | 1.01 (0.66, 1.48) | 0.957 | 37.18 |
| | Insulin | 1.09 (0.73, 1.59) | 0.674 | 35.45 | 1.11 (0.74, 1.62) | 0.589 | 33.36 |
| Psychosis ARMS | Leptin | 0.95 (0.61, 1.40) | 0.793 | 36.58 | 1.21 (0.72, 2.00) | 0.449 | 22.96 |
| | Adiponectin | 0.98 (0.65, 1.45) | 0.938 | 37.08 | 0.94 (0.63, 1.39) | 0.780 | 36.27 |
| | Insulin | 0.87 (0.59, 1.26) | 0.494 | 31.34 | 0.91 (0.62, 1.31) | 0.629 | 34.92 |

301

302 3.2.2 Sex-Stratified Analysis

303 The associations of leptin with depressive episode (aOR=1.42; 95% CI 1.04-1.91), depressive
304 symptoms (aOR=1.09; 95% CI 1.01-1.18) and negative symptoms (aOR=1.18; 95% CI 1.07-1.29)
305 were stronger in women, as was the associations of adiponectin (aOR=1.07; 95% CI 1.01-1.13)
306 and of insulin (aOR =1.08; 95% CI 1.01-1.14) with negative symptoms, although credible intervals
307 overlapped with those for men (**Supplementary Tables 9&10**).

308 3.3 Associations of childhood immuno-metabolic factor scores with depression and 309 psychosis risk in adulthood

310 3.3.1 Whole Sample Analysis


311 The general immuno-metabolic factor, *G*, was associated with depression symptom score
312 (OR=1.05; 95% CI 1.01-1.08) and psychotic experiences at age 24 (aOR=1.20; 95% CI 1.01-1.42,
313 **Figure 3, Table 2**). The adiposity factor was associated with negative symptoms (aOR=1.07; 95%
314 CI 1.02-1.12).

315 3.3.2 Sex-Stratified Analysis

316 There was stronger evidence of association between *G* and psychopathology in women than men.
317 In women, *G* was associated with depression symptom score (aOR=1.05; 95% CI 1.01-1.09),
318 atypical depression (aOR=1.07; 95% CI 1.00-1.15), and psychotic experiences (aOR=1.25; 95% CI
319 1.01-1.52, **Supplementary Tables 11&12**) although credible intervals overlapped with those for
320 men.

321 The inflammatory factor was associated with depressive episodes (aOR=1.23; 95% CI 1.01-1.47)
322 and atypical depressive symptoms in women (aOR=1.10; 95% CI 1.02-1.19). The adiposity factor
323 was associated with negative symptoms in women (aOR=1.09; 95% CI 1.03-1.16). The insulin
324 resistance factor was not associated with any psychiatric outcomes at age 24. However, point
325 estimates for the association between the insulin resistance factor and psychosis-related outcomes
326 (PEs, ARMS, psychotic disorder) were considerably larger in men compared with women, although
327 credible intervals were relatively wide (**Figure 3**).

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis



328

329 *Figure 3: Associations of Childhood Immuno-Metabolic Factors with Adult Depression and*
 330 *Psychosis Measures in the Whole Sample*

331 Plots of estimated odds ratios for the effect of factor scores derived from a bifactor EFA model
 332 (general factor (G) and three subfactors:(1) adiposity (ADI), (2) inflammation (INF) and (3) insulin
 333 resistance (IR) on psychiatric outcomes at age 24. Data are adjusted (for maternal social class and
 334 sex in the all-participant model) and grouped by model: either all participants, only females or only
 335 males. Thin bars represent the 95% credible interval, thicker bars the 66% credible interval, and
 336 dots the median of the posterior distribution for that parameter.

337

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

338 *Table 2: Associations of Childhood Immuno-Metabolic Factors with Adult Depression and*
 339 *Psychosis Measures in the Whole Sample*

| Outcome | Exposure (Immuno-metabolic Factors) | Estimated OR (95% CI) | pd | ROPE (%) |
|--------------------------------------|------------------------------------------------|----------------------------------|-----------|---------------------|
| Depressive Episode | General factor | 1.02 (0.87, 1.18) | 0.843 | 79.33 |
| | Adiposity factor | 1.14 (0.97, 1.35) | 0.121 | 34.71 |
| | Inflammation factor | 1.13 (0.97, 1.33) | 0.141 | 40.11 |
| | Insulin resistance factor | 1.04 (0.88, 1.22) | 0.670 | 73.37 |
| Depressive Symptoms Score | General factor | 1.05 (1.01, 1.08) | 0.008 | 99.97 |
| | Adiposity factor | 1.03 (0.99, 1.07) | 0.107 | 99.98 |
| | Inflammation factor | 0.99 (0.96, 1.03) | 0.626 | 100.00 |
| | Insulin resistance factor | 0.98 (0.95, 1.02) | 0.328 | 100.00 |
| Atypical Depressive Symptom Score | General factor | 1.06 (1.00, 1.12) | 0.063 | 93.41 |
| | Adiposity factor | 1.03 (0.97, 1.10) | 0.339 | 98.12 |
| | Inflammation factor | 1.06 (1.00, 1.13) | 0.069 | 91.38 |
| | Insulin resistance factor | 0.99 (0.93, 1.05) | 0.796 | 99.83 |
| Negative Symptoms Score | General factor | 0.97 (0.93, 1.01) | 0.130 | 99.92 |
| | Adiposity factor | 1.07 (1.02, 1.12) | 0.005 | 92.45 |
| | Inflammation factor | 1.03 (0.99, 1.07) | 0.191 | 99.98 |
| | Insulin resistance factor | 1.00 (0.95, 1.04) | 0.861 | 100.00 |
| Psychotic Experiences | General factor | 1.20 (1.01, 1.42) | 0.029 | 15.84 |
| | Adiposity factor | 1.12 (0.93, 1.36) | 0.226 | 41.93 |
| | Inflammation factor | 1.02 (0.85, 1.22) | 0.850 | 69.88 |
| | Insulin resistance factor | 0.97 (0.81, 1.16) | 0.754 | 70.36 |
| Psychotic Disorder | General factor | 0.90 (0.62, 1.32) | 0.570 | 34.57 |
| | Adiposity factor | 1.09 (0.72, 1.59) | 0.673 | 34.12 |
| | Inflammation factor | 1.27 (0.86, 1.82) | 0.234 | 19.64 |

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

| | Insulin resistance factor | 1.10 (0.75, 1.65) | 0.621 | 33.89 |
|----------------|---------------------------|-------------------|-------|-------|
| Psychosis ARMS | General factor | 0.76 (0.50, 1.13) | 0.171 | 16.25 |
| | Adiposity factor | 0.98 (0.63, 1.47) | 0.942 | 35.86 |
| | Inflammation factor | 0.96 (0.64, 1.44) | 0.854 | 36.54 |
| | Insulin resistance factor | 1.17 (0.79, 1.73) | 0.427 | 28.33 |

340

341 3.4 Missing Data

342 Out of total 15,645 participants enrolled in ALSPAC at inception, 3,875 contributed clinic and
343 covariate data up to age 9, and up to 3,966 participants contributed psychiatric data at age 24
344 (**Supplementary Table 13**). A maximum of 1,611 participants contributed both exposure and
345 outcome data (~10% of the total cohort, ~40% of all participants with outcome data). Therefore,
346 there was substantial missingness in our dataset.

347 In a sample of participants who contributed all demographic, age 9 immuno-metabolic exposures
348 and covariate data (n = 3,863), male sex (aOR=2.32; 95% CI 2.02-2.68), lower maternal education
349 (aOR=0.39; 95% CI 0.29-0.50), lower maternal social class (aOR=0.62; 95% CI 0.40-0.95), and
350 higher adiponectin levels at age 9 (aOR=1.08; 95% CI 1.01-1.16) were associated with missing
351 psychiatric outcome data at age 24 (**Supplementary Table 14**).

352 4. Discussion

353 4.1 Main Findings

354 Using data from a prospective birth cohort, we report that childhood leptin and adiponectin are
355 associated with largely affective symptoms (depression and psychosis negative symptoms) in
356 adulthood. Evidence for these associations remained after controlling for covariates including BMI
357 and inflammation and was stronger in women. Exploratory Factor Analysis of metabolic and
358 inflammatory biomarkers revealed an underlying structure of covariance, where a general immuno-
359 metabolic factor was associated with both depressive symptoms and psychotic experiences. We
360 also identified three specific factors. Leptin and BMI loaded onto the adiposity factor, which was
361 associated with negative symptoms. The inflammatory factor was associated with depressive
362 episode and atypical depressive symptoms in women. We found no associations between the
363 insulin resistance factor and psychiatric outcomes, although the point estimates for psychosis-
364 related outcomes were considerably larger in men than women.

365 4.2 Comparison with Previous Studies

366 The association between leptin and negative symptoms is in keeping with a meta-analysis of
367 patients with schizophrenia (Stubbs et al., 2016), although this was not observed in smaller studies
368 of first episode of psychosis (FEP) patients (Chouinard et al., 2019; Lis et al., 2020). However, in
369 FEP cases Lis et al., (2020) observed a correlation between leptin and cognitive dysfunction, a
370 domain of psychopathology somewhat linked to negative symptoms. Recently, a Mendelian
371 randomisation (MR) study did not find an association between leptin and schizophrenia (Perry et
372 al., 2021a), bringing into question whether leptin plays a causal role in the illness. It is worth noting
373 that this MR analysis relied on GWAS of schizophrenia, and not that of negative symptoms
374 specifically. Therefore, replication of our findings in other longitudinal cohorts, as well as evidence
375 triangulation using complementary methods like MR based on GWAS of negative symptoms are
376 required to fully understand the relationship between leptin and negative symptoms.

377 Lack of association between childhood random insulin levels, or the insulin resistance factor, and
378 positive psychotic symptoms at age 24 is consistent with a previous study from the ALSPAC cohort

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

379 testing association between fasting insulin and psychosis-spectrum outcomes at age 18 (Perry et
380 al., 2019). However, using longitudinal repeat measure data, Perry et al., (2021b) recently reported
381 that persistently raised fasting insulin levels through childhood and adolescence is associated with
382 psychosis risk at age 24. Together, these findings suggest that persistently high leptin during
383 development is likely relevant for adult psychosis, rather than one-off measures which do not
384 consider variation in leptin levels over time. Nevertheless, similar to Perry et al., (2021b), we
385 observed stronger association between the insulin resistance factor and psychosis-related
386 outcomes in men compared with women, suggesting that early-life insulin resistance may
387 contribute to psychosis risk in men particularly.

388 4.3 Potential mechanism of associations of immuno-metabolic markers and 389 depressive and psychotic symptoms

390 We observed that adiposity and inflammation were largely associated with negative and atypical
391 depressive symptoms. There is a rich literature suggesting a role of low-grade systemic
392 inflammation in depression (Khandaker et al., 2017; Milaneschi et al., 2021, 2020). Our findings
393 are consistent with a previous genetic study showing that cases of atypical depression (defined by
394 increased appetite and/or weight) have higher genetic predisposition for obesity and inflammation,
395 particularly genetic risk variants for BMI, leptin, and CRP (Milaneschi et al., 2017). Similarly, recent
396 MR studies from the UK Biobank and Dutch NESDA cohorts have reported associations of higher
397 BMI and IL-6 with specific depressive symptoms such as fatigue and appetite change
398 (Kappelmann et al., 2021; Milaneschi et al., 2021). The mechanism of the association between
399 inflammation and depression, particularly atypical depressive symptoms (Lamers et al., 2020), has
400 been hypothesised to involve the activation of sickness-related behaviours by inflammatory
401 cytokines, which directly affect neuroendocrine systems involved in regulating mood and
402 homeostatic functions such as sleep and appetite (Milaneschi et al., 2020). Further work is needed
403 to understand how leptin, and adiposity in general, contribute to negative symptoms.

404 Negative symptoms are common in schizophrenia, with prevalence exceeding 50% (Bobes et al.,
405 2010), and are a major contributor to morbidity (Fervaha et al., 2014; Iasevoli et al., 2018).

406 Furthermore, there is only a limited evidence base for effective treatments for these symptoms

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

407 (Galderisi et al., 2021). Previous work suggests two latent factors underlying negative symptoms,
408 namely reduced expression and amotivation (Bucci and Galderisi, 2017). Studies in schizophrenia
409 suggest an association between amotivational negative symptoms and altered reward processing,
410 which involves brain regions associated with the dopamine system including the ventral striatum
411 and medial prefrontal cortex (Strauss et al., 2016; Vanes et al., 2018; Wang et al., 2015; Wolf et
412 al., 2014). Leptin has been demonstrated to both indirectly and directly affect the activity of
413 midbrain dopamine neurons in animal models (Hommel et al., 2006; Leininger et al., 2009), as
414 has adiponectin (Sun et al., 2019). Furthermore, a relationship between inflammation, brain reward
415 systems and negative symptoms has been proposed (Goldsmith and Rapaport, 2020), which leptin
416 could also modulate, given evidence of its interactions with immune system (Abella et al., 2017;
417 Pulito-Cueto et al., 2020). Therefore, adipokines could have a direct influence on immune and
418 neural networks involved in the pathogenesis of negative symptoms.

419 4.4 Strengths and Limitations

420 We used prospective data with exposures measured approximately 15 years prior to that of
421 outcomes. We used a Bayesian approach to our statistical analysis, which is relatively novel and
422 allowed the incorporation of prior information, and the generation of point estimates and credible
423 intervals which have a more intuitive and robust interpretation than frequentist confidence intervals
424 and p-values (Wagenmakers et al., 2018).

425 Limitations include missing data and pattern of missingness. Participants were not missing
426 completely at random. Analysis of missingness in exposure data revealed that social class, and
427 education influenced participation in the study. The complete case data came from a group from
428 higher social class and higher educated families. One of the exposures, adiponectin, was
429 associated with missingness, which might have introduced bias. Furthermore, >97% of the
430 ALSPAC cohort is of white ethnicity, and so representativeness is an issue, and further studies in
431 more diverse populations are required.

432 We used an exploratory factor analysis approach to derive immuno-metabolic factors. In future,
433 confirmation of these findings in an independent dataset using confirmatory factor analysis is

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

434 required. Bifactor models have a tendency to overfitting (Bonifay and Cai, 2017) and we were
435 limited to nine immuno-metabolic biomarkers available from the age 9 ALSPAC cohort clinic
436 assessment. In future, inclusion of a wider range of biomarkers may help to improve latent factor
437 estimation. Nevertheless, without pre-specifying the biomarkers that might contribute to each latent
438 factor, we identified three specific factors (adiposity, inflammation, and insulin resistance)
439 composed of individual biomarkers with established, intuitive links with each factor, giving our
440 findings face validity.

441 Methods for calculating factor scores are imprecise, and scores are inherently indeterminate
442 (Grice, 2001). Therefore, the use of extracted factor scores as exposures in separate models may
443 have introduced error. However, the approach of combining factor scores with other datasets for
444 further analysis, including by Bayesian approaches, has been previously applied (Dam et al., 2017;
445 Gagne et al., 2020), and can contribute exploratory information to inform future studies. A future
446 approach that combines (potentially longitudinally measured) biomarkers with latent factors and
447 psychiatric outcomes in a single (Bayesian) structural equation model might inform a deeper
448 understanding of the relationship between individual biomarkers, useful intermediate concepts
449 (latent factors), and individual symptoms or psychopathological constructs.

450 4.5 Conclusions

451 Using a prospective cohort study, we report that childhood levels of the metabolic hormones leptin
452 and adiponectin are associated with depressive and negative symptoms in early adulthood. These
453 associations are stronger in women than men. Somewhat distinct associations were seen for
454 immuno-metabolic factor scores, which were derived from nine immuno-metabolic measures.
455 While a general immuno-metabolic factor was associated with both depressive and psychotic
456 symptoms, inflammation and adiposity were particularly associated with affective (depressive,
457 atypical depressive, and negative) symptoms. Together, these findings are consistent with the idea
458 that childhood immuno-metabolic alterations may contribute to risk of depressive and psychotic
459 disorders in adulthood.

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

460 Acknowledgements

461 The authors would like to thank Nils Kappelmann for valuable discussions about statistical analysis
462 and atypical depression. We are extremely grateful to all the families who took part in this study, the
463 midwives for their help in recruiting them, and the whole ALSPAC team, which includes interviewers,
464 computer and laboratory technicians, clerical workers, research scientists, volunteers, managers,
465 receptionists and nurses. The views expressed are those of the authors and not necessarily those of
466 the NIHR or the Department of Health and Social Care.

467

468 Funding Sources

469 The UK Medical Research Council and Wellcome (Grant ref: 217065/Z/19/Z) and the University of
470 Bristol provide core support for ALSPAC. A comprehensive list of grant funding is available on the
471 ALSPAC website (<http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf>).
472 The outcome data from age 24 was specifically funded by MRC grants MR/L022206/1 and
473 MR/M006727/1.

474 NAD acknowledges funding support from a National Institute for Health Research Academic Clinical
475 Fellowship in Mental Health. BIP acknowledges funding support from the National Institute for Health
476 Research (NIHR) (Doctoral Research Fellowship Grant No. DRF-2018-11-ST2-018). HJJ
477 acknowledges support from the NIHR Bristol Biomedical Research Centre. GMK acknowledges
478 funding support from the Wellcome Trust (Grant No. 201486/Z/16/Z), the Medical Research Council
479 (Grant No. MC_PC_17213, Grant No. MR/S037675/1, and Grant No. MR/W014416/1), The MQ:
480 Transforming Mental Health (Grant No. MQDS17/40), and the BMA Foundation (J. Moulton Grant
481 2019).

482 Competing Interests

483 The authors declare they have no competing interests

484

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

485 **CRedit author statement**

486 Nicholas Donnelly: Conceptualisation; Software; Data Curation; Formal Analysis; Visualization; Writing

487 – Original Draft

488 Benjamin Perry: Data Curation; Writing – Review & Editing

489 Hannah Jones: Writing – Reviewing & Editing

490 Golam Khandaker: Conceptualization; Supervision; Writing – Reviewing & Editing; Funding acquisition

491 **References**

- 492 Abella, V., Scotece, M., Conde, J., Pino, J., Gonzalez-Gay, M.A., Gómez-Reino, J.J., Mera, A., Lago,
493 F., Gómez, R., Gualillo, O., 2017. Leptin in the interplay of inflammation, metabolism and
494 immune system disorders. *Nat. Rev. Rheumatol.* 13, 100–109.
495 <https://doi.org/10.1038/nrrheum.2016.209>
- 496 Benros, M.E., Nielsen, P.R., Nordentoft, M., Eaton, W.W., Dalton, S.O., Mortensen, P.B., 2011.
497 Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year
498 population-based register study. *Am. J. Psychiatry* 168, 1303–1310.
499 <https://doi.org/10.1176/appi.ajp.2011.11030516>
- 500 Benseñor, I.M., Brunoni, A.R., Pilan, L.A., Goulart, A.C., Busatto, G.F., Lotufo, P.A., Scazufca, M.,
501 Menezes, P.R., 2012. Cardiovascular risk factors in patients with first-episode psychosis in São
502 Paulo, Brazil. *Gen. Hosp. Psychiatry* 34, 268–275.
503 <https://doi.org/10.1016/j.genhosppsy.2011.12.010>
- 504 Bobes, J., Arango, C., Garcia-Garcia, M., Rejas, J., CLAMORS Study Collaborative Group, 2010.
505 Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated
506 with antipsychotics in routine clinical practice: findings from the CLAMORS study. *J. Clin.*
507 *Psychiatry* 71, 280–286. <https://doi.org/10.4088/JCP.08m04250yel>
- 508 Bonifay, W., Cai, L., 2017. On the Complexity of Item Response Theory Models. *Multivar. Behav. Res.*
509 52, 465–484. <https://doi.org/10.1080/00273171.2017.1309262>
- 510 Boyd, A., Golding, J., Macleod, J., Lawlor, D.A., Fraser, A., Henderson, J., Molloy, L., Ness, A., Ring,
511 S., Davey Smith, G., 2013. Cohort Profile: The ‘Children of the 90s’—the index offspring of the
512 Avon Longitudinal Study of Parents and Children. *Int. J. Epidemiol.* 42, 111–127.
513 <https://doi.org/10.1093/ije/dys064>
- 514 Bucci, P., Galderisi, S., 2017. Categorizing and assessing negative symptoms. *Curr. Opin. Psychiatry*
515 30, 201–208. <https://doi.org/10.1097/YCO.0000000000000322>
- 516 Bürkner, P.-C., 2017. brms: An R Package for Bayesian Multilevel Models Using Stan. *J. Stat. Softw.*
517 80, 1–28. <https://doi.org/10.18637/jss.v080.i01>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 518 Carpenter, B., Gelman, A., Hoffman, M.D., Lee, D., Goodrich, B., Betancourt, M., Brubaker, M., Guo,
519 J., Li, P., Riddell, A., 2017. Stan: A Probabilistic Programming Language. *J. Stat. Softw.* 76, 1–
520 32. <https://doi.org/10.18637/jss.v076.i01>
- 521 Chouinard, V.-A., Henderson, D.C., Man, C.D., Valeri, L., Gray, B.E., Ryan, K.P., Cypess, A.M.,
522 Cobelli, C., Cohen, B.M., Öngür, D., 2019. Impaired insulin signaling in unaffected siblings and
523 patients with first episode psychosis. *Mol. Psychiatry* 24, 1513–1522.
524 <https://doi.org/10.1038/s41380-018-0045-1>
- 525 Considine, R.V., Sinha, M.K., Heiman, M.L., Kriauciunas, A., Stephens, T.W., Nyce, M.R.,
526 Ohannesian, J.P., Marco, C.C., McKee, L.J., Bauer, T.L., Caro, J.F., 1996. Serum
527 Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans. *N. Engl. J. Med.*
528 334, 292–295. <https://doi.org/10.1056/NEJM199602013340503>
- 529 Dam, N.T.V., O'Connor, D., Marcelle, E.T., Ho, E.J., Craddock, R.C., Tobe, R.H., Gabbay, V.,
530 Hudziak, J.J., Castellanos, F.X., Leventhal, B.L., Milham, M.P., 2017. Data-Driven Phenotypic
531 Categorization for Neurobiological Analyses: Beyond DSM-5 Labels. *Biol. Psychiatry* 81, 484–
532 494. <https://doi.org/10.1016/j.biopsych.2016.06.027>
- 533 Eaton, W.W., Byrne, M., Ewald, H., Mors, O., Chen, C.-Y., Agerbo, E., Mortensen, P.B., 2006.
534 Association of schizophrenia and autoimmune diseases: linkage of Danish national registers.
535 *Am. J. Psychiatry* 163, 521–528. <https://doi.org/10.1176/appi.ajp.163.3.521>
- 536 Falaschetti, E., Hingorani, A.D., Jones, A., Charakida, M., Finer, N., Whincup, P., Lawlor, D.A., Davey
537 Smith, G., Sattar, N., Deanfield, J.E., 2010. Adiposity and cardiovascular risk factors in a large
538 contemporary population of pre-pubertal children. *Eur. Heart J.* 31, 3063–3072.
539 <https://doi.org/10.1093/eurheartj/ehq355>
- 540 Fervaha, G., Foussias, G., Agid, O., Remington, G., 2014. Motivational and neurocognitive deficits are
541 central to the prediction of longitudinal functional outcome in schizophrenia. *Acta Psychiatr.*
542 *Scand.* 130, 290–299. <https://doi.org/10.1111/acps.12289>
- 543 Fraser, A., Macdonald-Wallis, C., Tilling, K., Boyd, A., Golding, J., Davey Smith, G., Henderson, J.,
544 Macleod, J., Molloy, L., Ness, A., Ring, S., Nelson, S.M., Lawlor, D.A., 2013. Cohort Profile:
545 The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort. *Int. J.*
546 *Epidemiol.* 42, 97–110. <https://doi.org/10.1093/ije/dys066>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 547 Fried, E.I., 2017. The 52 symptoms of major depression: Lack of content overlap among seven
548 common depression scales. *J. Affect. Disord.* 208, 191–197.
549 <https://doi.org/10.1016/j.jad.2016.10.019>
- 550 Gagne, C., Zika, O., Dayan, P., Bishop, S.J., 2020. Impaired adaptation of learning to contingency
551 volatility in internalizing psychopathology. *eLife* 9, e61387. <https://doi.org/10.7554/eLife.61387>
- 552 Galderisi, S., Kaiser, S., Bitter, I., Nordentoft, M., Mucci, A., Sabé, M., Giordano, G.M., Nielsen, M.Ø.,
553 Glenthøj, L.B., Pezzella, P., Falkai, P., Dollfus, S., Gaebel, W., 2021. EPA guidance on
554 treatment of negative symptoms in schizophrenia. *Eur. Psychiatry* 64, e21.
555 <https://doi.org/10.1192/j.eurpsy.2021.13>
- 556 Gimeno, D., Kivimäki, M., Brunner, E.J., Elovainio, M., De Vogli, R., Steptoe, A., Kumari, M., Lowe,
557 G.D.O., Rumley, A., Marmot, M.G., Ferrie, J.E., 2009. Associations of C-reactive protein and
558 interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study.
559 *Psychol. Med.* 39, 413–423. <https://doi.org/10.1017/S0033291708003723>
- 560 Golding, Pembrey, Jones, Team, T.A.S., 2001. ALSPAC—The Avon Longitudinal Study of Parents and
561 Children. *Paediatr. Perinat. Epidemiol.* 15, 74–87. [https://doi.org/10.1046/j.1365-
562 3016.2001.00325.x](https://doi.org/10.1046/j.1365-3016.2001.00325.x)
- 563 Goldsmith, D.R., Rapaport, M.H., 2020. Inflammation and Negative Symptoms of Schizophrenia:
564 Implications for Reward Processing and Motivational Deficits. *Front. Psychiatry* 11, 46.
565 <https://doi.org/10.3389/fpsy.2020.00046>
- 566 Grice, J., 2001. Computing and evaluating factor scores. *Psychol. Methods* 6, 430–50.
- 567 Harris, P.A., Taylor, R., Minor, B.L., Elliott, V., Fernandez, M., O’Neal, L., McLeod, L., Delacqua, G.,
568 Delacqua, F., Kirby, J., Duda, S.N., REDCap Consortium, 2019. The REDCap consortium:
569 Building an international community of software platform partners. *J. Biomed. Inform.* 95,
570 103208. <https://doi.org/10.1016/j.jbi.2019.103208>
- 571 Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., 2009. Research electronic
572 data capture (REDCap)—a metadata-driven methodology and workflow process for providing
573 translational research informatics support. *J. Biomed. Inform.* 42, 377–381.
574 <https://doi.org/10.1016/j.jbi.2008.08.010>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 575 Hoang, U., Goldacre, M.J., Stewart, R., 2013. Avoidable mortality in people with schizophrenia or
576 bipolar disorder in England. *Acta Psychiatr. Scand.* 127, 195–201.
577 <https://doi.org/10.1111/acps.12045>
- 578 Hommel, J.D., Trinko, R., Sears, R.M., Georgescu, D., Liu, Z.W., Gao, X.B., Thurmon, J.J., Marinelli,
579 M., DiLeone, R.J., 2006. Leptin receptor signaling in midbrain dopamine neurons regulates
580 feeding. *Neuron* 51, 801–810.
- 581 Iasevoli, F., Avagliano, C., Altavilla, B., Barone, A., D'Ambrosio, L., Matrone, M., Notar Francesco, D.,
582 Razzino, E., de Bartolomeis, A., 2018. Disease Severity in Treatment Resistant Schizophrenia
583 Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive
584 Dysfunctions and Neurological Soft Signs. *Front. Psychiatry* 9, 553.
585 <https://doi.org/10.3389/fpsy.2018.00553>
- 586 Jerry, R.G., Lesley, V.C., 2006. Relationship Between Inflammation, Insulin Resistance and Type 2
587 Diabetes: Cause or Effect? *Curr. Diabetes Rev.* 2, 195–211.
- 588 Jones, H.J., Stergiakouli, E., Tansey, K.E., Hubbard, L., Heron, J., Cannon, M., Holmans, P., Lewis,
589 G., Linden, D.E.J., Jones, P.B., Davey Smith, G., O'Donovan, M.C., Owen, M.J., Walters, J.T.,
590 Zammit, S., 2016. Phenotypic Manifestation of Genetic Risk for Schizophrenia During
591 Adolescence in the General Population. *JAMA Psychiatry* 73, 221.
592 <https://doi.org/10.1001/jamapsychiatry.2015.3058>
- 593 Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M.,
594 Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation,
595 and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian
596 Randomization Study. *JAMA Psychiatry* 78, 161–170.
597 <https://doi.org/10.1001/jamapsychiatry.2020.3436>
- 598 Khandaker, G.M., Dantzer, R., Jones, P.B., 2017. Immunopsychiatry: important facts. *Psychol. Med.*
599 47, 2229–2237. <https://doi.org/10.1017/S0033291717000745>
- 600 Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of serum
601 interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult
602 life: a population-based longitudinal study. *JAMA Psychiatry* 71, 1121–1128.
603 <https://doi.org/10.1001/jamapsychiatry.2014.1332>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 604 Konings, M., Bak, M., Hanssen, M., van Os, J., Krabbendam, L., 2006. Validity and reliability of the
605 CAPE: a self-report instrument for the measurement of psychotic experiences in the general
606 population. *Acta Psychiatr. Scand.* 114, 55–61. [https://doi.org/10.1111/j.1600-](https://doi.org/10.1111/j.1600-0447.2005.00741.x)
607 [0447.2005.00741.x](https://doi.org/10.1111/j.1600-0447.2005.00741.x)
- 608 Kruschke, J.K., Liddell, T.M., 2018. Bayesian data analysis for newcomers. *Psychon. Bull. Rev.* 25,
609 155–177. <https://doi.org/10.3758/s13423-017-1272-1>
- 610 Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H., 2020.
611 Depression profilers and immuno-metabolic dysregulation: Longitudinal results from the
612 NESDA study. *Brain. Behav. Immun.* 88, 174–183. <https://doi.org/10.1016/j.bbi.2020.04.002>
- 613 Leininger, G.M., Jo, Y.-H., Leshan, R.L., Louis, G.W., Yang, H., Barrera, J.G., Wilson, H., Opland,
614 D.M., Faouzi, M.A., Gong, Y., 2009. Leptin Acts via Leptin Receptor-Expressing Lateral
615 Hypothalamic Neurons to Modulate the Mesolimbic Dopamine System and Suppress Feeding.
616 *Cell Metab.* 10, 89–98. <https://doi.org/10.1016/j.cmet.2009.06.011>
- 617 Lewis, G., Pelosi, A.J., Araya, R., Dunn, G., 1992. Measuring psychiatric disorder in the community: a
618 standardized assessment for use by lay interviewers. *Psychol. Med.* 22, 465–486.
619 <https://doi.org/10.1017/s0033291700030415>
- 620 Lis, M., Stańczykiewicz, B., Pawlik-Sobecka, L., Samochowiec, A., Regina, A., Misiak, B., 2020.
621 Assessment of Appetite-Regulating Hormones Provides Further Evidence of Altered
622 Adipoinular Axis in Early Psychosis. *Front. Psychiatry* 11, 480.
623 <https://doi.org/10.3389/fpsy.2020.00480>
- 624 Makowski, D., Ben-Shachar, M.S., Chen, S.H.A., Lüdecke, D., 2019a. Indices of Effect Existence and
625 Significance in the Bayesian Framework. *Front. Psychol.* 10.
626 <https://doi.org/10.3389/fpsyg.2019.02767>
- 627 Makowski, D., Ben-Shachar, M.S., Lüdecke, D., 2019b. bayestestR: Describing Effects and their
628 Uncertainty, Existence and Significance within the Bayesian Framework. *J. Open Source*
629 *Softw.* 4, 1541. <https://doi.org/10.21105/joss.01541>
- 630 McElreath, R., 2018. *Statistical Rethinking: A Bayesian Course with Examples in R and Stan,*
631 *Statistical Rethinking: A Bayesian Course with Examples in R and Stan.*
632 <https://doi.org/10.1201/9781315372495>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 633 Metcalf, S.A., Jones, P.B., Nordstrom, T., Timonen, M., Mäki, P., Miettunen, J., Jääskeläinen, E.,
634 Järvelin, M.-R., Stochl, J., Murray, G.K., Veijola, J., Khandaker, G.M., 2017. Serum C-reactive
635 protein in adolescence and risk of schizophrenia in adulthood: A prospective birth cohort study.
636 *Brain. Behav. Immun.* 59, 253–259. <https://doi.org/10.1016/j.bbi.2016.09.008>
- 637 Milaneschi, Y., Kappelmann, N., Ye, Z., Lamers, F., Moser, S., Jones, P.B., Burgess, S., Penninx,
638 B.W.J.H., Khandaker, G.M., 2021. Association of inflammation with depression and anxiety:
639 evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts.
640 *Mol. Psychiatry.* <https://doi.org/10.1038/s41380-021-01188-w>
- 641 Milaneschi, Y., Lamers, F., Berk, M., Penninx, B.W.J.H., 2020. Depression Heterogeneity and Its
642 Biological Underpinnings: Toward Immunometabolic Depression. *Biol. Psychiatry, Molecular*
643 *Underpinnings of Depression and Its Treatment* 88, 369–380.
644 <https://doi.org/10.1016/j.biopsych.2020.01.014>
- 645 Milaneschi, Y., Lamers, F., Peyrot, W.J., Baune, B.T., Breen, G., Dehghan, A., Forstner, A.J., Grabe,
646 H.J., Homuth, G., Kan, C., Lewis, C., Mullins, N., Nauck, M., Pistis, G., Preisig, M., Rivera, M.,
647 Rietschel, M., Streit, F., Strohmaier, J., Teumer, A., Van der Auwera, S., Wray, N.R.,
648 Boomsma, D.I., Penninx, B.W.J.H., for the CHARGE Inflammation Working Group and the
649 Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium, 2017.
650 Genetic Association of Major Depression With Atypical Features and Obesity-Related
651 Immunometabolic Dysregulations. *JAMA Psychiatry* 74, 1214–1225.
652 <https://doi.org/10.1001/jamapsychiatry.2017.3016>
- 653 Milaneschi, Y., Simmons, W.K., van Rossum, E.F.C., Penninx, B.W., 2019. Depression and obesity:
654 evidence of shared biological mechanisms. *Mol. Psychiatry* 24, 18–33.
655 <https://doi.org/10.1038/s41380-018-0017-5>
- 656 Northstone, K., Lewcock, M., Groom, A., Boyd, A., Macleod, J., Timpson, N., Wells, N., 2019. The
657 Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample
658 of index children in 2019. *Wellcome Open Res.* 4, 51.
659 <https://doi.org/10.12688/wellcomeopenres.15132.1>
- 660 Ong, K.K., Petry, C.J., Emmett, P.M., Sandhu, M.S., Kiess, W., Hales, C.N., Ness, A.R., Dunger, D.B.,
661 ALSPAC study team, 2004. Insulin sensitivity and secretion in normal children related to size at

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 662 birth, postnatal growth, and plasma insulin-like growth factor-I levels. *Diabetologia* 47, 1064–
663 1070. <https://doi.org/10.1007/s00125-004-1405-8>
- 664 Osimo, E.F., Baxter, L.J., Lewis, G., Jones, P.B., Khandaker, G.M., 2019. Prevalence of low-grade
665 inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol.*
666 *Med.* 49, 1958–1970. <https://doi.org/10.1017/S0033291719001454>
- 667 Penninx, B.W., Beekman, A.T., Honig, A., Deeg, D.J., Schoevers, R.A., van Eijk, J.T., van Tilburg, W.,
668 2001. Depression and cardiac mortality: results from a community-based longitudinal study.
669 *Arch. Gen. Psychiatry* 58, 221–227. <https://doi.org/10.1001/archpsyc.58.3.221>
- 670 Perry, B.I., Burgess, S., Jones, H.J., Zammit, S., Upthegrove, R., Mason, A.M., Day, F.R.,
671 Langenberg, C., Wareham, N.J., Jones, P.B., Khandaker, G.M., 2021a. The potential shared
672 role of inflammation in insulin resistance and schizophrenia: A bidirectional two-sample
673 mendelian randomization study. *PLoS Med.* 18, e1003455.
674 <https://doi.org/10.1371/journal.pmed.1003455>
- 675 Perry, B.I., McIntosh, G., Weich, S., Singh, S., Rees, K., 2016. The association between first-episode
676 psychosis and abnormal glycaemic control: systematic review and meta-analysis. *Lancet*
677 *Psychiatry* 3, 1049–1058. [https://doi.org/10.1016/S2215-0366\(16\)30262-0](https://doi.org/10.1016/S2215-0366(16)30262-0)
- 678 Perry, B.I., Stochl, J., Upthegrove, R., Zammit, S., Wareham, N., Langenberg, C., Winpenny, E.,
679 Dunger, D., Jones, P.B., Khandaker, G.M., 2021b. Longitudinal Trends in Childhood Insulin
680 Levels and Body Mass Index and Associations With Risks of Psychosis and Depression in
681 Young Adults. *JAMA Psychiatry*. <https://doi.org/10.1001/jamapsychiatry.2020.4180>
- 682 Perry, B.I., Upthegrove, R., Thompson, A., Marwaha, S., Zammit, S., Singh, S.P., Khandaker, G.,
683 2019. Dysglycaemia, Inflammation and Psychosis: Findings From the UK ALSPAC Birth
684 Cohort. *Schizophr. Bull.* 45, 330–338. <https://doi.org/10.1093/schbul/sby040>
- 685 Pillinger, T., Beck, K., Gobjila, C., Donocik, J.G., Jauhar, S., Howes, O.D., 2017. Impaired Glucose
686 Homeostasis in First-Episode Schizophrenia: A Systematic Review and Meta-analysis. *JAMA*
687 *Psychiatry* 74, 261–269. <https://doi.org/10.1001/jamapsychiatry.2016.3803>
- 688 Pulito-Cueto, V., Remuzgo-Martínez, S., Genre, F., Calvo-Alén, J., Aurrecochea, E., Llorente, I.,
689 Triguero-Martinez, A., Blanco, R., Llorca, J., Ruiz-Lucea, E., Rivera-García, N., Gualillo, O.,

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 690 López-Mejías, R., Castañeda, S., González-Gay, M.A., 2020. Anti-IL-6 therapy reduces leptin
691 serum levels in patients with rheumatoid arthritis. *Clin. Exp. Rheumatol.*
- 692 R Development Core Team, 2017. R: A Language and environment for statistical computing. Vienna
693 Austria R Found. Stat. Comput.
- 694 Stefanis, N.C., Hanssen, M., Smirnis, N.K., Avramopoulos, D.A., Evdokimidis, I.K., Stefanis, C.N.,
695 Verdoux, H., Van Os, J., 2002. Evidence that three dimensions of psychosis have a distribution
696 in the general population. *Psychol. Med.* 32, 347–358.
697 <https://doi.org/10.1017/s0033291701005141>
- 698 Strauss, G.P., Whearty, K.M., Morra, L.F., Sullivan, S.K., Ossenfort, K.L., Frost, K.H., 2016. Avolition
699 in schizophrenia is associated with reduced willingness to expend effort for reward on a
700 Progressive Ratio task. *Schizophr. Res.* 170, 198–204.
701 <https://doi.org/10.1016/j.schres.2015.12.006>
- 702 Stubbs, B., Wang, A.K., Vancampfort, D., Miller, B.J., 2016. Are leptin levels increased among people
703 with schizophrenia versus controls? A systematic review and comparative meta-analysis.
704 *Psychoneuroendocrinology* 63, 144–154. <https://doi.org/10.1016/j.psyneuen.2015.09.026>
- 705 Sullivan, S.A., Kounali, D., Cannon, M., David, A.S., Fletcher, P.C., Holmans, P., Jones, H., Jones,
706 P.B., Linden, D.E.J., Lewis, G., Owen, M.J., O'Donovan, M., Rammos, A., Thompson, A.,
707 Wolke, D., Heron, J., Zammit, S., 2020. A Population-Based Cohort Study Examining the
708 Incidence and Impact of Psychotic Experiences From Childhood to Adulthood, and Prediction
709 of Psychotic Disorder. *Am. J. Psychiatry* 177, 308–317.
710 <https://doi.org/10.1176/appi.ajp.2019.19060654>
- 711 Sun, F., Lei, Y., You, J., Li, C., Sun, L., Garza, J., Zhang, D., Guo, M., Scherer, P.E., Lodge, D., Lu,
712 X.-Y., 2019. Adiponectin modulates ventral tegmental area dopamine neuron activity and
713 anxiety-related behavior through AdipoR1. *Mol. Psychiatry* 24, 126–144.
714 <https://doi.org/10.1038/s41380-018-0102-9>
- 715 Timpson, N.J., Nordestgaard, B.G., Harbord, R.M., Zacho, J., Frayling, T.M., Tybjaerg-Hansen, A.,
716 Davey Smith, G., 2011. C-reactive protein levels and body mass index: elucidating direction of
717 causation through reciprocal Mendelian randomization. *Int. J. Obes.* 35, 300–308.
718 <https://doi.org/10.1038/ijo.2010.137>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 719 van Dielen, F.M.H., van't Veer, C., Schols, A.M., Soeters, P.B., Buurman, W.A., Greve, J.W.M., 2001.
720 Increased leptin concentrations correlate with increased concentrations of inflammatory
721 markers in morbidly obese individuals. *Int. J. Obes.* 25, 1759–1766.
722 <https://doi.org/10.1038/sj.ijo.0801825>
- 723 van Melle, J.P., de Jonge, P., Spijkerman, T.A., Tijssen, J.G.P., Ormel, J., van Veldhuisen, D.J., van
724 den Brink, R.H.S., van den Berg, M.P., 2004. Prognostic association of depression following
725 myocardial infarction with mortality and cardiovascular events: a meta-analysis. *Psychosom.*
726 *Med.* 66, 814–822. <https://doi.org/10.1097/01.psy.0000146294.82810.9c>
- 727 Vancampfort, D., Stubbs, B., Mitchell, A.J., Hert, M.D., Wampers, M., Ward, P.B., Rosenbaum, S.,
728 Correll, C.U., 2015. Risk of metabolic syndrome and its components in people with
729 schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder:
730 a systematic review and meta-analysis. *World Psychiatry* 14, 339–347.
731 <https://doi.org/10.1002/wps.20252>
- 732 Vanes, L.D., Mouchlianitis, E., Collier, T., Averbeck, B.B., Shergill, S.S., 2018. Differential neural
733 reward mechanisms in treatment-responsive and treatment-resistant schizophrenia. *Psychol.*
734 *Med.* 48, 2418–2427. <https://doi.org/10.1017/S0033291718000041>
- 735 Wagenmakers, E.-J., Marsman, M., Jamil, T., Ly, A., Verhagen, J., Love, J., Selker, R., Gronau, Q.F.,
736 Šmíra, M., Epskamp, S., Matzke, D., Rouder, J.N., Morey, R.D., 2018. Bayesian inference for
737 psychology. Part I: Theoretical advantages and practical ramifications. *Psychon. Bull. Rev.* 25,
738 35–57. <https://doi.org/10.3758/s13423-017-1343-3>
- 739 Wang, J., Huang, J., Yang, X.-H., Lui, S.S.Y., Cheung, E.F.C., Chan, R.C.K., 2015. Anhedonia in
740 schizophrenia: Deficits in both motivation and hedonic capacity. *Schizophr. Res.* 168, 465–474.
741 <https://doi.org/10.1016/j.schres.2015.06.019>
- 742 Wolf, D.H., Satterthwaite, T.D., Kantrowitz, J.J., Katchmar, N., Vandekar, L., Elliott, M.A., Ruparel, K.,
743 2014. Amotivation in schizophrenia: integrated assessment with behavioral, clinical, and
744 imaging measures. *Schizophr. Bull.* 40, 1328–1337. <https://doi.org/10.1093/schbul/sbu026>
- 745 Yudkin, J.S., Stehouwer, C.D.A., Emeis, J.J., Coppack, S.W., 1999. C-Reactive Protein in Healthy
746 Subjects: Associations With Obesity, Insulin Resistance, and Endothelial Dysfunction.
747 *Arterioscler. Thromb. Vasc. Biol.* 19, 972–978. <https://doi.org/10.1161/01.ATV.19.4.972>

Donnelly et al: Immuno-metabolic Markers, Depression and Psychosis

- 748 Zalli, A., Jovanova, O., Hoogendijk, W.J.G., Tiemeier, H., Carvalho, L.A., 2016. Low-grade
749 inflammation predicts persistence of depressive symptoms. *Psychopharmacology (Berl.)* 233,
750 1669–1678. <https://doi.org/10.1007/s00213-015-3919-9>
- 751 Zammit, S., Kounali, D., Cannon, M., David, A.S., Gunnell, D., Heron, J., Jones, P.B., Lewis, S.,
752 Sullivan, S., Wolke, D., Lewis, G., 2013. Psychotic experiences and psychotic disorders at age
753 18 in relation to psychotic experiences at age 12 in a longitudinal population-based cohort
754 study. *Am. J. Psychiatry* 170, 742–750. <https://doi.org/10.1176/appi.ajp.2013.12060768>
755